ReviewFrontiers in pharmacology2026
Early biomarkers associated with prenatal alcohol exposure and neurodevelopmental outcomes.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prenatal alcohol exposure (PAE) is a major early-life stressor associated with long-lasting neurodevelopmental and neurocognitive alterations. Increasing evidence from human studies indicates that PAE leaves persistent molecular signatures that can be detected in the placenta and in clinically accessible biological fluids. This Mini Review summarizes recent advances in the identification of epigenetic, immune, endocrine, and RNA-based biomarkers measured in placental tissue, umbilical cord blood, and peripheral fluids, and their associations with neurodevelopmental outcomes. We highlight convergent findings across heterogeneous study designs, discuss current methodological challenges and research gaps, and consider future directions toward integrative and longitudinal biomarker approaches. Together, the reviewed evidence supports the potential of placental and circulating biomarkers to improve early risk stratification and to advance understanding of neurodevelopmental alterations following PAE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.